Long-term humoral and cellular immunity after primary SARS-CoV-2 infection: a 20-month longitudinal study.

Autor: Hvidt AK; Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark., Guo H; CellCarta, Montreal, QC, Canada., Andersen R; Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark., Lende SSF; Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark., Vibholm LK; Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark., Søgaard OS; Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark., Schleimann MH; Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark., Russell V; Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada., Cheung AM; Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada.; Department of Medicine, University Health Network, Toronto, ON, Canada.; Department of Medicine, University of Toronto, Toronto, ON, Canada.; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada., Paramithiotis E; CellCarta, Montreal, QC, Canada., Olesen R; Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark. rikkol@rm.dk.; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. rikkol@rm.dk., Tolstrup M; Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Jazyk: angličtina
Zdroj: BMC immunology [BMC Immunol] 2023 Nov 16; Vol. 24 (1), pp. 45. Date of Electronic Publication: 2023 Nov 16.
DOI: 10.1186/s12865-023-00583-y
Abstrakt: Background: SARS-CoV-2 remains a world-wide health issue. SARS-CoV-2-specific immunity is induced upon both infection and vaccination. However, defining the long-term immune trajectory, especially after infection, is limited. In this study, we aimed to further the understanding of long-term SARS-CoV-2-specific immune response after infection.
Results: We conducted a longitudinal cohort study among 93 SARS-CoV-2 recovered individuals. Immune responses were continuously monitored for up to 20 months after infection. The humoral responses were quantified by Spike- and Nucleocapsid-specific IgG levels. T cell responses to Spike- and non-Spike epitopes were examined using both intercellular cytokine staining (ICS) assay and Activation-Induced marker (AIM) assay with quantification of antigen-specific IFNγ production. During the 20 months follow-up period, Nucleocapsid-specific antibody levels and non-Spike-specific CD4 + and CD8 + T cell frequencies decreased in the blood. However, a majority of participants maintained a durable immune responses 20 months after infection: 59% of the participants were seropositive for Nucleocapsid-specific IgG, and more than 70% had persisting non-Spike-specific T cells. The Spike-specific response initially decreased but as participants were vaccinated against COVID-19, Spike-specific IgG levels and T cell frequencies were boosted reaching similar or higher levels compared to 1 month post-infection. The trajectory of infection-induced SARS-CoV-2-specific immunity decreases, but for the majority of participants it persists beyond 20 months. The T cell response displays a greater durability. Vaccination boosts Spike-specific immune responses to similar or higher levels as seen after primary infection.
Conclusions: For most participants, the response persists 20 months after infection, and the cellular response appears to be more long-lived compared to the circulating antibody levels. Vaccination boosts the S-specific response but does not affect the non-S-specific response. Together, these findings support the understanding of immune contraction, and with studies showing the immune levels required for protection, adds to the knowledge of durability of protection against future SARS-CoV-2.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje